Vericel Corporation VCEL
At closeNov 4, 2026, 5:03 PM EST
After hours · Nov 4, 5:03 PM ET
- YTD
- +26.30%
- 1 year
- +25.46%
- Market cap
- 2.33B
- Revenue (ttm)
- 306.30M
- Profit margin
- 7.91%
- EPS (ttm)
- 0.47
- Shares out
- 51.21M
- P/E ratio
- 96.77
- Forward P/E
- 53.76
- YTD return
- +26.30%
- 1-year return
- +25.46%
- Volume
- 1.81M
- Avg volume
- 519.35K
- Open
- 42.07
- Previous close
- 41.09
- Day's range
- 42.07 – 45.98
- 52-week range
- 28.95 – 49.32
- Beta
- 1.06
- Price target
- 59.71 (+31.3%)
- Earnings date
- Nov 5, 2026
2Y +0.73 (+1.63%)
Key statistics
- Enterprise value
- 2.03B
- PEG ratio
- 0.00
- Price / sales
- 7.60
- Price / book
- 6.29
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 22.50%
- Free cash flow
- 55.54M
- Total cash
- 162.46M
- Total debt
- 93.13M
- Return on equity
- 7.16%
- Short % of float
- 13.18%
- 50-day average
- 40.51
- 200-day average
- 38.68
Analyst view
- Target (low)
- 52.00
- Target (mean)
- 59.71
- Target (high)
- 72.00
- Strong buy0
- Buy7
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.056.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.0575 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | -0.02894 | 0.04 | +0.07 | +238.22% |
| May 7, 2026 | Mar 31, 2026 | -0.15 | -0.12 | +0.03 | +20.00% |
| Feb 26, 2026 | Dec 31, 2025 | 0.45 | 0.45 | 0.00 | 0.00% |
| Nov 6, 2025 | Sep 30, 2025 | -0.02 | 0.10 | +0.12 | +600.00% |
| Jul 31, 2025 | Jun 30, 2025 | -0.04 | -0.01 | +0.03 | +75.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | Truist Securities | main | Buy | Buy |
| Jul 31, 2026 | TD Cowen | main | Buy | Buy |
| Jul 31, 2026 | Truist Securities | reit | Buy | Buy |
| Jul 31, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 28, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 16, 2026 | Truist Securities | main | Buy | Buy |
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vcel.com
News
Alkermes (NASDAQ:ALKS) vs. Vericel (NASDAQ:VCEL) Head to Head Contrast 
Comparing Vericel (NASDAQ:VCEL) and Zymeworks (NASDAQ:ZYME) 
Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026 
Truist Securities Maintains Buy on Vericel, Lowers Price Target to $52 
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript 
Vericel: MACI And Regenerative Knee Cartilage 
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026 
Canada Pension Plan Investment Board Takes Position in Vericel Corporation $VCEL 
Vericel Corporation $VCEL Shares Purchased by Bank of America Corp DE 
TD Cowen Maintains Buy on Vericel, Raises Price Target to $58
Your note
Sign in to keep a note on VCEL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COLANGELO DOMINICK C | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 23, 2026 | 312,446 |
| HAGEN HEIDI M. | Director | Conversion of Exercise of derivative security | Apr 28, 2026 | 35,050 |
| HALPIN MICHAEL | Chief Operating Officer | Sale | Aug 2, 2026 | 16,394 |
| HOPPER JONATHAN MARK | Officer | Sale | Jun 25, 2026 | 75,753 |
| MARA JOSEPH ANTHONY JR | Chief Financial Officer | Sale | Jun 25, 2026 | 16,009 |
| MCLAUGHLIN KEVIN F | Director | Sale | Aug 11, 2026 | 18,300 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.80% | 8,092,226 | 368.03M | Jun 29, 2026 |
| State Street Corporation | 6.43% | 3,293,975 | 149.81M | Jun 29, 2026 |
| Congress Asset Management Co | 4.98% | 2,552,066 | 116.07M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.41% | 2,255,728 | 102.59M | Jun 29, 2026 |
| William Blair Investment Management, LLC | 3.89% | 1,992,855 | 90.64M | Jun 29, 2026 |
| BNP Paribas Asset Management Holding S.A. | 3.20% | 1,639,988 | 74.59M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 3,047,921 | 138.62M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.16% | 1,617,188 | 73.55M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.59% | 1,328,230 | 60.41M | Sep 29, 2026 |
| Conestoga Funds-Conestoga Small Cap Fund | 2.55% | 1,307,355 | 59.46M | Jun 29, 2026 |
| Professionally Managed Portfolios-Congress Small Cap Growth Fund | 2.28% | 1,165,000 | 52.98M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.15% | 1,103,424 | 50.18M | Sep 29, 2026 |